--- title: "Inhibikase Therapeutics (IKT) news: merger" url: "https://aibio.space/companies/inhibikase-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IKT merger news: Inhibikase acquires CorHepta in merger, paying $15.0 million in 4,979,101 shares of stock. Inhibikase Therapeutics, Inc." --- IKT Inhibikase Therapeutics, Inc. NASDAQ · United States # Inhibikase Therapeutics (IKT) news IKT merger news Financings · 2026-07-29 ## [RA Capital exchanges 18,030,000 Inhibikase Therapeutics shares for a pre-funded warrant](https://aibio.space/news/ra-capital-exchanges-18-030-000-inhibikase-therapeutics-shares-pre/) On July 29, 2026, RA Capital Healthcare Fund exchanged 18,030,000 Inhibikase common shares for a pre-funded warrant on the same number of shares. The warrant carries a 9.99% ownership limit, and the filing does not say why the exchange was made. ## Latest Inhibikase Therapeutics news 1. 2025-02-24 Financings [Inhibikase acquires CorHepta in merger, paying $15.0 million in 4,979,101 shares of stock](https://aibio.space/news/inhibikase-acquires-corhepta-merger-paying-15-0-million-4-979-101/) Inhibikase paid $15.0 million for CorHepta in 4,979,101 newly issued shares, with part held in escrow or tied to a milestone. The 8-K names no bank, placement agent or financial adviser for the stock issuance. ## Inhibikase Therapeutics at a glance - **Ticker**: IKT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $159.0 million ### Related companies - [Belite Bio](https://aibio.space/companies/belite-bio/) NASDAQ: BLTE - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) NASDAQ: TENX - [Kaleido Biosciences](https://aibio.space/companies/kaleido-biosciences/) OTC: KLDO - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Oruka Therapeutics](https://aibio.space/companies/oruka-therapeutics/) NASDAQ: ORKA - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) AMEX: ATNM - [EyePoint](https://aibio.space/companies/eyepoint/) NASDAQ: EYPT - [Bolt Biotherapeutics](https://aibio.space/companies/bolt-biotherapeutics/) NASDAQ: BOLT ### Also on NASDAQ - [GRAIL](https://aibio.space/companies/grail/) GRAL - [RenovoRx](https://aibio.space/companies/renovorx/) RNXT - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) LTGO - [Axogen](https://aibio.space/companies/axogen/) AXGN - [Sutro Biopharma](https://aibio.space/companies/sutro-biopharma/) STRO - [Novavax](https://aibio.space/companies/novavax/) NVAX ## What Inhibikase Therapeutics does Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, starting with pulmonary arterial hypertension, or PAH, which is an orphan indication. Its lead product candidate is IKT-001, a prodrug of imatinib. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders, and the company notes that after more than 20 years of clinical use it has a well-characterized safety profile. The first reported use of imatinib in PAH occurred in 2005. PAH is a progressive, life-threatening disease that affects approximately 50,000 Americans. The company describes aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor known as c-Kit, as implicated in the disease. Inhibikase has completed a non-human primate safety study and a bioequivalence clinical study in healthy volunteers to determine the doses of IKT-001. It plans to initiate Phase 3 trials in PAH in multiple countries to support regulatory approval. Its subsidiaries are IKT Securities Corporation and CorHepta Pharmaceuticals, Inc. | Product or program | What it is | Stage | |---|---|---| | IKT-001 | Prodrug of imatinib for pulmonary arterial hypertension, an orphan indication | Phase 3 planned in PAH | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm). ## Inhibikase Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$0](https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/) | | Research and development | [$29.8 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | [$17.2 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | | Net income (loss) | [-$48.3 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | [-$27.5 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | | Cash from operations | [-$27.8 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | [-$19.1 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | | Cash and equivalents | [$178.8 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | [$97.5 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | | Short-term investments | [$39.5 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344707/) | [$41.1 million](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $31.2 million, plus short-term investments of $127.8 million, $159.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Inhibikase Therapeutics Is Inhibikase Therapeutics involved in a merger or acquisition? Our latest story on this, dated Feb 24, 2025: "Inhibikase acquires CorHepta in merger, paying $15.0 million in 4,979,101 shares of stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inhibikase-acquires-corhepta-merger-paying-15-0-million-4-979-101/). What is the ticker symbol of Inhibikase Therapeutics? Inhibikase Therapeutics, Inc. trades under the ticker IKT on NASDAQ. Where is Inhibikase Therapeutics listed? Inhibikase Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Inhibikase Therapeutics? The SEC Central Index Key (CIK) for Inhibikase Therapeutics, Inc. is 1750149. Its filings are on SEC EDGAR. How many shares does Inhibikase Therapeutics have outstanding? 139,535,900 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Inhibikase Therapeutics listed under? Our directory records Inhibikase Therapeutics, Inc. under United States. What does Inhibikase Therapeutics do? Our directory classifies Inhibikase Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Inhibikase Therapeutics? The ISIN recorded for Inhibikase Therapeutics, Inc. is US45719W2052. Does aibio.space cover Inhibikase Therapeutics? aibio.space lists Inhibikase Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Inhibikase Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Inhibikase Therapeutics develop? Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, starting with pulmonary arterial hypertension, or PAH, which is an orphan indication. Its lead product candidate is IKT-001, a prodrug of imatinib. What is IKT-001 from Inhibikase Therapeutics? IKT-001: Prodrug of imatinib for pulmonary arterial hypertension, an orphan indication Stage: Phase 3 planned in PAH. Is Inhibikase Therapeutics profitable? Inhibikase Therapeutics, Inc. reported a net loss of $48.3 million for the fiscal year ended Dec 31, 2025, and used $27.8 million of cash in operations, per its annual report to the SEC. How much does Inhibikase Therapeutics spend on research and development? $29.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Inhibikase Therapeutics have? $159.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Inhibikase Therapeutics Members talk about Inhibikase Therapeutics (IKT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Inhibikase Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-26 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/d904831d8k.htm) 2. 2026-07-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/d78217d8k.htm) 3. 2026-07-14 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/d157026dex991.htm) 4. 2025-12-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312525326883/d39077d424b5.htm) 5. 2025-11-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312525289894/d944552d424b5.htm) 6. 2025-06-20 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm) 7. 2025-02-24 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/d889659dex991.htm) 8. 2025-02-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312525028188/d835160dex991.htm) 9. 2025-01-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/d909904d8k.htm) 10. 2024-12-05 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1750149/000119312524271609/d914736d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IKT on TradingView](https://www.tradingview.com/symbols/NASDAQ-IKT/). ## SEC filings and registration - **SEC name**: Inhibikase Therapeutics, Inc. - **CIK**: 1750149 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IKT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801 - **Phone**: (302) 295-3800 - **Shares outstanding**: 139,535,900 as of 2026-08-04 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/d190975d8k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526385293/d152999d8k.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526368296/d904831d8k.htm) filed 2026-08-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344707/ikt-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059d8k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/d78217d8k.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526313400/d121491d8k.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/d157026d8k.htm) filed 2026-07-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001750149), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Inhibikase Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IKT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Inhibikase Therapeutics, Inc. - **Ticker**: IKT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US45719W2052 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IKT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/inhibikase-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Inhibikase Therapeutics (IKT) news: merger", 2026-10-31, https://aibio.space/companies/inhibikase-therapeutics/